Potent inhibition of human immunodeficiency virus type 1 (HIV-1) gene expression and virus production by an HIV-2 Tat activation-response RNA decoy

Journal of Virology

Volumn 73, Issue 6, 1999, Pages 5191-5195

  Browning, Catherine M ^a   Cagnon, Laurence ^b   Good, Paul D ^a   Rossi, John ^b   Engelke, David R ^a   Markovitz, David M ^a,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SMALL NUCLEAR RNA; TRANSACTIVATOR PROTEIN; VIRUS RNA;

ARTICLE; CONTROLLED STUDY; EXPRESSION VECTOR; GENE EXPRESSION; GENE THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; TRANSACTIVATION; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

EID: 0033065431     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.73.6.5191-5195.1999     Document Type: Article

References (44)

1. Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
2. Aldovini, A., and B. D. Walker. 1990. Techniques in HIV research. Stockton Press, New York, N.Y.
3. Al-Harthi, L., M. Owais, and S. K. Arya. 1998. Molecular inhibition of HIV type 1 by HIV type 2: effectiveness in peripheral blood mononuclear cells. AIDS Res. Human Retroviruses 14:59-64.
4. Ariyoshi, K., M. Schim van der Loeff, S. Sabally, F. Cham, T. Corrah, and H. Whittle. 1997. Does HIV-2 infection provide cross-protection against HIV-1 infection? AIDS 11:1053-1053.
5. Arya, S. K., and R. C. Gallo. 1996. Human immunodeficiency virus (HIV) type 2-mediated inhibition of HIV type 1: a new approach to gene therapy of HIV-infection. Proc. Natl. Acad. Sci. USA 93:4486-4491.
6. Arya, S. K., C. Guo, S. F. Josephs, and F. Wong-Staal. 1985. Transactivator gene of human T-lymphotropic virus type III (HTLV-III). Science 229:69-73.
7. Bohjanen, P. R., R. A. Culvin, M. Puttaraju, M. D. Been, and M. A. Garcia-Blanco. 1996. A small circular TAR RNA decoy specifically inhibits Tat-activated HIV-1 transcription. Nucleic Acids Res. 24:3733-3738.
8. Bohjanen, P. R., Y. Liu, and M. A. Garcia-Blanco. 1997. TAR RNA decoys inhibit tat-activated HIV-1 transcription after preinitiation complex formation. Nucleic Acids Res. 25:4481-4481.
9. Bonyhadi, M. L., K. Moss, A. Voytovich, J. Auten, C. Kalfoglou, I. Plavec, S. Forestell, L. Su, E. Bohnlein, and H. Kaneshima. 1997. RevM10-expressing T cells derived in vivo from transduced human hematopoietic stem-progenitor cells inhibit human immunodeficiency virus replication. J. Virol. 71: 4707-4716.
10. Browning, C., J. M. Hilfinger, S. Rainier, V. Lin, S. Hedderwick, M. Smith, and D. M. Markovitz. 1997. The sequence and structure of the 3′ arm of the first stem-loop of the human immunodeficiency virus type 2 trans-activation responsive region mediate Tat-2 transactivation. J. Virol. 71:8048-8055.
11. Cagnon, L., M. Cucchiarini, J. C. Lefebvre, and A. Doglio. 1995. Protection of a T-cell line from human immunodeficiency virus replication by the stable expression of a short antisense RNA sequence carried by a shuttle RNA molecule. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 9:349-358.
12. Chang, Y. N., and K. T. Jeang. 1992. The basic RNA-binding domain of HIV-2 Tat contributes to preferential trans-activation of a TAR2-containing LTR. Nucleic Acids Res. 20:5465-5472.
13. Cujec, T. P., H. Okamoto, K. Fujinaga, J. Meyer, H. Chamberlin, D. O. Morgan, and B. M. Peterlin. 1997. The HIV transactivator TAT binds to the CDK-activating kinase and activates the phosphorylation of the carboxy-terminal domain of RNA polymerase II. Genes Dev. 11(20):2645-2657.
14. Dayton, A. I., J. G. Sodroski, C. A. Rosen, W. C. Goh, and W. A. Haseltine. 1986. The trans-activator gene of the human T cell lymphotropic virus type III is required for replication. Cell 44:941-947.
15. Emerman, M., M. Guyader, L. Montagnier, D. Baltimore, and M. A. Muesing. 1987. The specificity of the human immunodeficiency virus type 2 transactivator is different from that of human immunodeficiency virus type I. EMBO J. 6:3755-3760.
16. Emerman, M., and M. H. Malim. 1998. HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology. Science 280:1880-1884.
17. Fenrick, R., M. H. Malim, J. Hauber, S. Y. Le, J. Maizel, and B. R. Cullen. 1989. Functional analysis of the Tat trans activator of human immunodeficiency virus type 2. J. Virol. 63:5006-5012.
18. Finzi, D., M. Hermankova, T. Pierson, L. M. Carruth, C. Buck, R. E. Chaisson, T. C. Quinn, K. Chadwick, J. Margolick, R. Brookmeyer, J. Gallant, M. Markowitz, D. D. Ho, D. D. Richman, and R. F. Siliciano. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295-1300.
19. Fisher, A. G., M. B. Feinberg, S. F. Josephs, M. E. Harper, L. M. Marselle, G. Reyes, M. A. Gonda, A. Aldovini, C. Debouk, and R. C. Gallo. 1986. The trans-activator gene of HTLV-III is essential for virus replication. Nature 320:367-371.
20. Garcia-Martinez, L. F., G. Mavankal, P. Peters, F. Wu-Baer, and R. B. Gaynor. 1995. Tat functions to stimulate the elongation properties of transcription complexes paused by the duplicated TAR RNA element of human immunodeficiency virus 2. J. Mol. Biol. 254:350-363.
21. Gaynor, R. B. 1995. Regulation of HIV-1 gene expression by the transactivator protein Tat. Curr. Top. Microbiol. Immunol. 193:51-77.
22. Gilboa, E., and C. Smith. 1994. Gene therapy for infectious diseases: the AIDS model. Trends Genet. 10:139-144.
23. Good, P. D., A. J. Krikos, S. X. Li, E. Bertrand, N. S. Lee, L. Giver, A. Ellington, J. A. Zaia, J. J. Rossi, and D. R. Engelke. 1997. Expression of small, therapeutic RNAs in human cell nuclei. Gene Ther. 4:45-54.
24. Hahn, B. H., G. M. Shaw, S. K. Arya, M. Popovic, R. C. Gallo, and F. Wong-Staal. 1984. Molecular cloning and characterization of the HTLV-III virus associated with AIDS. Nature 312:166-169.
25. Herrmann, C. H., and A. P. Rice. 1995. Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor. J. Virol. 69:1612-1620.
26. Lee, S. W., H. F. Gallardo, O. Caspar, C. Smith, and E. Gilboa. 1995. Inhibition of HIV-1 in CEM cells by a potent TAR decoy. Gene Ther. 2:377-384.
27. Lever, A. M. 1995. Gene therapy for HIV infection. Br. Med. Bull. 51:149-166.
28. Lisziewicz, J., D. Sun, J. Smythe, P. Lusso, F. Lori, A. Louie, P. Markham, J. Rossi, M. Reitz, and R. C. Gallo. 1993. Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS. Proc. Natl. Acad. Sci. USA 90:8000-8004.
29. Malim, M. H., S. Bohnlein, J. Hauber, and B. R. Cullen. 1989. Functional dissection of the HIV-1 Rev trans-activator-derivation of a trans-dominant represser of Rev function. Cell 58:205-214.
30. Marciniak, R. A., B. J. Calnan, A. D. Frankel, and P. A. Sharp. 1990. HIV-1 Tat protein trans-activates transcription in vitro. Cell 63:791-802.
31. Markovitz, D. M. 1993. Infection with the human immunodeficiency virus type 2. Ann. Intern. Med. 118:211-218.
32. Nakaya, T., S. Iwai, K. Fujinaga, E. Otsuka, and K. Ikuta. 1997. Inhibition of HIV-1 replication by targeting the Rev protein. Leukemia 11(Suppl. 3): 134-137.
33. Parada, C. A., and R. G. Roeder. 1996. Enhanced processivity of RNA polymerase II triggered by Tat-induced phosphorylation of its carboxy-terminal domain. Nature 384:375-378.
34. Rappaport, J., S. K. Arya, M. W. Richardson, G. Baier-Bitterlich, and P. E. Klotman. 1995. Inhibition of HIV-1 expression by HIV-2. J. Mol. Med. 73:583-589.
35. Rhim, H., and A. P. Rice. 1994. Functional significance of the dinucleotide bulge in stem-loop1 and stem-loop2 of HIV-2 TAR RNA. Virology 202:202-211.
36. Rossi, J. Unpublished observations.
37. Tong-Starksen, S. E., A. Baur, X. B. Lu, E. Peck, and B. M. Peterlin. 1993. Second exon of Tat of HIV-2 is required for optimal trans-activation of HIV-1 and HIV-2 LTRs. Virology 195:826-830.
38. Travers, K. U., G. E. Eisen, R. G. Marlink, M. E. Essex, C. C. Hsieh. S. Mboup, and P. J. Kanki. 1998. Protection from HIV-1 infection by HIV-2. AIDS 12:224-225. (Letter; comment.)
39. Travers, K., S. Mboup, R. Marlink, A. Gueye-Ndiaye, T. Silby, I. Thior, I. Traore, A. Dieng-Sarr, J.-L. Sankale, C. Mullins, I. Ndoye, C.-C. Hsieh, M. Essex, and P. Kanki. 1995. Natural protection against HIV-1 infection provided by HIV-2. Science 268:1612-1615.
40. Wei, P., M. E. Garber, S. M. Fang, W. H. Fischer, and K. A. Jones. 1998. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 92:451-462.
41. Woffendin, C., U. Ranga, Z. Yang, L. Xu, and G. J. Nabel. 1996. Expression of a protective gene-prolongs survival of T cells in human immunodeficiency virus-infected patients. Proc. Natl. Acad. Sci. USA 93:2889-2894.
42. Wong, J. K., M. Hezareh, H. F. Gunthard, D. V. Havlir, C. C. Ignacio, C. A. Spina, and D. D. Richman. 1997. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278:1291-1295.
43. Yang, X., M. O. Gold, D. N. Tang, D. E. Lewis, E. Aguilar-Cordova, A. P. Rice, and C. H. Hermann. 1997. TAK, an HIV Tat-associated kinase, is a member of the cyclin-dependent family of protein kinases and is induced by activation of peripheral blood lymphocytes and differentiation of promonocytic cell lines. Proc. Natl. Acad. Sci. USA 94:12331-12336.
44. Zhu, Y., T. Pe-ery, J. Peng, Y. Ramanathan, N. Marshall, T. Marshall, B. Amendt, M. B. Mathews, and D. H. Price. 1997. Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. Genes Dev. 11:2622-2632.